title: Intensive induction chemotherapy followed by high dose chemotherapy with autologous hematopoietic progenitor cell rescue in young children newly diagnosed with central nervous system atypical teratoid rhabdoid tumors.
abstract: BACKGROUND
  Central nervous system (CNS) atypical teratoid rhabdoid tumors (AT/RT) are rare tumors of childhood with a dismal prognosis. Historically, surgery and standard dose chemotherapy have resulted in a median survival of 8.5 months from diagnosis.
  
  
  METHODS
  Thirteen children newly diagnosed with CNS AT/RT were treated with either the "Head Start I" (HS I) or "Head Start II" (HS II) regimens. Therapy included resection followed by five cycles of cisplatin, vincristine, cyclophosphamide, and etoposide. High dose methotrexate was added to each of the five induction courses in HS II. Consolidation for both regimens included carboplatin, thiotepa, and etoposide with autologous hematopoietic progenitor cell rescue (AHPCR).
  
  
  RESULTS
  Six children, median age of 36 months, were treated on HS I between 1992 and 1997. Seven children, median age of 28 months, were treated on HS II between 1997 and 2002. One patient received craniospinal irradiation following AHPCR but prior to recurrence. There are presently three event-free survivors 42+, 54+, and 67+ months following diagnosis; none received RT. All three survivors were enrolled on HS II. Eight patients died of disease (six on HS I); one patient died from infection; one patient died from secondary malignancy following treatment for recurrent AT/RT.
  
  
  CONCLUSIONS
  Three of seven children with CNS AT/RT treated on HS II have experienced long term remissions. Long term survival can be achieved in a subset of young children with CNS AT/RT following resection with the use of multi-drug chemotherapy including high dose methotrexate and myeloablative chemotherapy without radiation therapy (RT).
authors.affiliation: Department of Pediatrics, New York University, New York, New York 10016, USA. sharon.gardner@nyumc.org
authors.forename: Sharon L
authors.initials: SL
authors.lastname: Gardner
authors.forename: Shahab
authors.initials: S
authors.lastname: Asgharzadeh
authors.forename: Adam
authors.initials: A
authors.lastname: Green
authors.forename: Biljana
authors.initials: B
authors.lastname: Horn
authors.forename: Geoffrey
authors.initials: G
authors.lastname: McCowage
authors.forename: Jonathan
authors.initials: J
authors.lastname: Finlay
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000401:mortality / Q000628:therapy*; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007223:Infant; D008297:Male; D018335:Rhabdoid Tumor / Q000401:mortality / Q000628:therapy*; D013724:Teratoma / Q000401:mortality / Q000628:therapy*; D014182:Transplantation, Autologous